Cover Image
市場調查報告書

藥物成癮:開發中產品分析

Drug Addiction - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 251560
出版日期 內容資訊 英文 162 Pages
訂單完成後即時交付
價格
Back to Top
藥物成癮:開發中產品分析 Drug Addiction - Pipeline Review, H2 2017
出版日期: 2017年07月25日 內容資訊: 英文 162 Pages
簡介

藥物成癮又稱物質成癮,如果達到破壞性模式,對物質的抗性和擺脫依賴會有很大的困難。藥物成癮患者主要的症狀、行動,由於藥物頻繁的利用,無法進行在職場、學校、家庭的必要行動,會有失眠症,睡眠韻律的不規則化,異常的懶惰感,厭食症/過食症,飲食行動的變化,手掌的體溫降低、發汗,手的顫抖,眼睛充血、眼淚,瞳孔擴張/縮小,呼吸、人體、衣服異臭等。

本報告提供全球各國的藥物成癮治療用的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

藥物成癮概要

治療藥的開發

  • 藥物成癮開發中產品:概要
  • 藥物成癮開發中產品:各企業
  • 藥物成癮開發中產品:各大學/研究機關
  • 藥物成癮治療藥:開發中的產品一覽:各企業
  • 藥物成癮治療藥:各研究中的產品一覽:各大學/研究機關

藥物成癮:治療藥的評估

  • 各標的
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物成癮開發治療藥的企業

  • Addex Therapeutics Ltd
  • Aelis Farma SAS
  • Aphios Corp
  • BioCorRx Inc
  • Cerecor Inc
  • Chiesi Farmaceutici SpA
  • Curemark LLC
  • Egalet Corp
  • Embera NeuroTherapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Foresee Pharmaceuticals LLC
  • Heptares Therapeutics Ltd
  • Immunovaccine Inc
  • Indivior Plc
  • InterveXion Therapeutics LLC
  • Intra-Cellular Therapies Inc
  • 杏林藥業
  • Kyowa Hakko Kirin
  • Omeros Corp
  • Opiant Pharmaceuticals Inc
  • Orexigen Therapeutics Inc
  • P2D Bioscience
  • Saniona AB
  • Stada Arzneimittel AG
  • Teva Pharmaceutical Industries Ltd
  • Zynerba Pharmaceuticals Inc

藥物簡介

藥物成癮治療藥:開發暫停的產品

藥物成癮治療藥:開發中止的產品

藥物成癮相關產品的開發里程碑

  • 值得注意的最新趨勢、新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9580IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Drug Addiction - Pipeline Review, H2 2017, provides an overview of the Drug Addiction (Central Nervous System) pipeline landscape.

Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. Drug addiction symptoms or behaviors include recurrent drug use that results in a lack of meeting important obligations at work, school, or home, inability to sleep, awake at unusual times, unusual laziness, loss of or increased in appetite, changes in eating habits, cold, sweaty palms; shaking hands., red, watery eyes; pupils larger or smaller than usual and unusual smells on breath, body or clothes.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Drug Addiction - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Drug Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Drug Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Drug Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 7, 7, 1, 29, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 12 and 5 molecules, respectively.

Drug Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Addiction (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Drug Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Drug Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Drug Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Drug Addiction (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Drug Addiction (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Drug Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Drug Addiction - Overview
    • Drug Addiction - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
  • Products under Development by Universities/Institutes
    • Drug Addiction - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Addiction - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • Aelis Farma SAS
    • Aphios Corp
    • BioCorRx Inc
    • Cerecor Inc
    • Chiesi Farmaceutici SpA
    • Curemark LLC
    • Egalet Corp
    • Embera NeuroTherapeutics Inc
    • F. Hoffmann-La Roche Ltd
    • Foresee Pharmaceuticals LLC
    • Heptares Therapeutics Ltd
    • Immunovaccine Inc
    • Indivior Plc
    • InterveXion Therapeutics LLC
    • Intra-Cellular Therapies Inc
    • Kyorin Pharmaceutical Co Ltd
    • Kyowa Hakko Kirin Co Ltd
    • Omeros Corp
    • Opiant Pharmaceuticals Inc
    • Orexigen Therapeutics Inc
    • P2D Bioscience
    • Saniona AB
    • Stada Arzneimittel AG
    • Teva Pharmaceutical Industries Ltd
    • Zynerba Pharmaceuticals Inc
  • Drug Addiction - Drug Profiles
    • (acetaminophen + hydrocodone bitartrate + Respiratory Drug) - Drug Profile
    • (hydrocodone bitartrate + naltrexone hydrochloride) - Drug Profile
    • (metyrapone + oxazepam) - Drug Profile
    • 18-MC - Drug Profile
    • ADX-71441 - Drug Profile
    • ADX-71743 - Drug Profile
    • ADX-88178 - Drug Profile
    • AEF-0117 - Drug Profile
    • ANS-6637 - Drug Profile
    • AT-076 - Drug Profile
    • AT-089 - Drug Profile
    • AT-1001 - Drug Profile
    • AT-212 - Drug Profile
    • Biologic to Agonize TLR4 for Drug Addiction - Drug Profile
    • cannabidiol - Drug Profile
    • CERC-501 - Drug Profile
    • CM-1212 - Drug Profile
    • DDD-024 - Drug Profile
    • dronabinol - Drug Profile
    • dronabinol - Drug Profile
    • Drug for Addiction - Drug Profile
    • Enzyme for Cocaine Addiction - Drug Profile
    • EORA-101 - Drug Profile
    • EP-11313 - Drug Profile
    • FP-004 - Drug Profile
    • Gene Therapy to Activate Cocaine Hydrolase for Cocaine Abuse - Drug Profile
    • h-2E2 - Drug Profile
    • ibudilast - Drug Profile
    • istradefylline - Drug Profile
    • ITI-333 - Drug Profile
    • IXT-m200 - Drug Profile
    • JDTic - Drug Profile
    • JQ-1 - Drug Profile
    • KDAC-0001 - Drug Profile
    • levofacetoperane - Drug Profile
    • lofexidine hydrochloride - Drug Profile
    • MC-100093 - Drug Profile
    • naltrexone hydrochloride SR - Drug Profile
    • NLS-10 - Drug Profile
    • NS-2359 - Drug Profile
    • OMS-405 - Drug Profile
    • OMS-527 - Drug Profile
    • OPNT-001 - Drug Profile
    • OREX-1019 - Drug Profile
    • OREX-1038 - Drug Profile
    • oxycodone hydrochloride - Drug Profile
    • RBP-8000 - Drug Profile
    • Recombinant Enzyme for Cocaine Abuse - Drug Profile
    • RO-5256390 - Drug Profile
    • SERx-480 - Drug Profile
    • Small Molecule to Activate Kappa Opioid Receptor for CNS - Drug Profile
    • Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile
    • Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile
    • Small Molecules for Neonatal Abstinence Syndrome - Drug Profile
    • Small Molecules to Block VMAT2 for Methamphetamine Addiction - Drug Profile
    • Small Molecules to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction - Drug Profile
    • Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile
    • Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile
    • Small Molecules to Inhibit Kappa Opioid Receptor for CNS - Drug Profile
    • Small Molecules to Scavenge Free Radicals for Oxidative Stress Related Disorders - Drug Profile
    • Small Molecules to Target 5HT2 for CNS Disorders and Obesity - Drug Profile
    • Small Molecules to Target Nicotinic Acetylcholine Receptors for Drug Addiction and Drug Abuse - Drug Profile
    • Synthetic Peptide to Target Kappa Opioid Receptors for Drug Addiction - Drug Profile
    • Vaccine for Cocaine Addiction - Drug Profile
    • Vaccine for Drug Abuse - Drug Profile
    • Vaccine for Methamphetamine Abuse - Drug Profile
    • Vaccine for Methamphetamine Addiction - Drug Profile
    • VU-0463841 - Drug Profile
  • Drug Addiction - Dormant Projects
  • Drug Addiction - Discontinued Products
  • Drug Addiction - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Drug Addiction, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Drug Addiction - Pipeline by Addex Therapeutics Ltd, H2 2017
  • Drug Addiction - Pipeline by Aelis Farma SAS, H2 2017
  • Drug Addiction - Pipeline by Aphios Corp, H2 2017
  • Drug Addiction - Pipeline by BioCorRx Inc, H2 2017
  • Drug Addiction - Pipeline by Cerecor Inc, H2 2017
  • Drug Addiction - Pipeline by Chiesi Farmaceutici SpA, H2 2017
  • Drug Addiction - Pipeline by Curemark LLC, H2 2017
  • Drug Addiction - Pipeline by Egalet Corp, H2 2017
  • Drug Addiction - Pipeline by Embera NeuroTherapeutics Inc, H2 2017
  • Drug Addiction - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Drug Addiction - Pipeline by Foresee Pharmaceuticals LLC, H2 2017
  • Drug Addiction - Pipeline by Heptares Therapeutics Ltd, H2 2017
  • Drug Addiction - Pipeline by Immunovaccine Inc, H2 2017
  • Drug Addiction - Pipeline by Indivior Plc, H2 2017
  • Drug Addiction - Pipeline by InterveXion Therapeutics LLC, H2 2017
  • Drug Addiction - Pipeline by Intra-Cellular Therapies Inc, H2 2017
  • Drug Addiction - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017
  • Drug Addiction - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017
  • Drug Addiction - Pipeline by Omeros Corp, H2 2017
  • Drug Addiction - Pipeline by Opiant Pharmaceuticals Inc, H2 2017
  • Drug Addiction - Pipeline by Orexigen Therapeutics Inc, H2 2017
  • Drug Addiction - Pipeline by P2D Bioscience, H2 2017
  • Drug Addiction - Pipeline by Saniona AB, H2 2017
  • Drug Addiction - Pipeline by Stada Arzneimittel AG, H2 2017
  • Drug Addiction - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017
  • Drug Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H2 2017
  • Drug Addiction - Dormant Projects, H2 2017
  • Drug Addiction - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Drug Addiction - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Drug Addiction - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Drug Addiction, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top